NCT03573817 - A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

September 25, 2018

Study Completion Date

September 25, 2018

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Revefenacin

Revefenacin is administered via a nebulizer.

DRUG

Placebo

Placebo version of Revefenacin is administered via a nebulizer.

DRUG

Formoterol

Administered sequentially in both revefenacin and placebo arms using a nebulizer.

Trial Locations (12)

Theravance Biopharma Investigational Site, Erie

Theravance Biopharma Investigational Site, Monroe

Theravance Biopharma Investigational Site, Spartanburg

Theravance Biopharma Investigational Site, Gaffney

Theravance Biopharma Investigational Site, Greenville

Theravance Biopharma Investigational Site, Orlando

Theravance Biopharma Investigational Site, Miami

Theravance Biopharma Investigational Site, Tampa

Theravance Biopharma Investigational Site, Sarasota

Theravance Biopharma Investigational Site, Columbus

Theravance Biopharma Investigational Site, Saint Charles

Theravance Biopharma Investigational Site, Medford